Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Abordaje terapéutico en pericarditis recurrente resistente a colchicina en niños (CREATE)

16 de noviembre de 2026 actualizado por: Istituto Giannina Gaslini

Abordaje terapéutico en la pericarditis recurrente resistente a la colchicina en niños: un ensayo aleatorizado abierto que compara Anakinra con esteroides

The purpose of this study is to demonstrate that anakinra provides more rapid disease control than steroids in the first month of treatment in the event of recurrent pericarditis and is more effective in preventing further exacerbations in patients aged between eight months and eighteen years of age with idiopathic or post-procedural pericarditis, unresponsive to first-line treatment with NSAIDs and colchicine at the appropriate dosage, or in case of colchicine intolerance. The efficacy of the two treatments will be evaluated by the capacity and timing of the two therapies to determine a complete control (clinical, laboratory and instrumental) of the disease and the absence of recurrences.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Although steroids represent the second-line treatment for recurrent pericarditis (RP), to be used in case of inadequate response to NSAIDs and colchicine, their use is controversial due to their side effects.

Indeed, in adult patients with RP it has been demonstrated that the use of steroids is associated with an increased risk of recurrence: in a study carried out in adult patients, 64% of patients taking high-dose steroids (> 1 mg/kg/ of prednisone or equivalent), and 32% of patients taking this low-dose drug (< 1 mg/kg/day of prednisone or equivalent) relapsed. Furthermore, the therapy is associated with serious side effects and an increased risk of hospitalization, especially in patients treated with high doses. Finally, a high percentage of RP patients (both adult and pediatric) treated with steroids tend to become steroid-dependent, experiencing a disease exacerbation during tapering of treatment or soon after its discontinuation. The side effects associated with the chronic use of steroids are well known, especially in childhood, as their use is associated not only with reduced bone density, but also with growth retardation. Therefore, their long-term use is contraindicated, especially in children.

In a recent retrospective study of 58 pediatric patients with recurrent pericarditis treated with IL-1 inhibitors, a high steroid dependence rate was observed (45 of 48 treated patients). In this study, the presence of predictive factors associated with the possibility of achieving long-term remission was evaluated. Unfortunately, it could not be shown that avoiding steroid use was associated with an increased chance of withdrawing anakinra without relapse. This is likely due to the large variability of the cohort included in the retrospective study.

Therapy with anakinra in recurrent pericarditis is aimed at obtaining rapid and complete control of the disease and maintaining it over time, allowing the suspension of steroid therapy and thus reducing the risk of complications, chronicity and recurrence.

In the field of pediatric rheumatology, there is convincing evidence that in children with chronic arthritis a more aggressive therapy at an early stage can take advantage of the so-called "window of opportunity": according to this theory, early biological treatment can modify the pathogenetic mechanism of the disease by improving its long-term outcomes.

In particular, it has been shown that anakinra therapy in children with systemic JIA can lead to rapid attainment of inactive disease and allow for early discontinuation of treatment in the absence of recurrence in the majority of patients. Among all the rheumatological pathologies of the pediatric age, systemic JIA is the one that has the greatest similarities with autoinflammatory diseases due to the presence of fever, sometimes recurrent, rash and serositis, typical characteristics of AID, especially of inflammasomopathies. Recurrent pericarditis itself has many similarities to these conditions, as demonstrated by the efficacy of interleukin-1 inhibition. In fact, both of these conditions are considered by many to be real autoinflammatory diseases, with a multifactorial etiology. It is therefore reasonable to think that the concept of the "window of opportunity" can also be translated to recurrent pericarditis: the early blockade of cytokines could in fact abrogate the pathogenetic mechanism of the disease and therefore its chronic course and/or its relapses.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

48

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Bologna, Italia, 40138
        • Activo, no reclutando
        • Azienda Ospedaliero-Universitaria S.Orsola-Malpighi
      • Brescia, Italia, 25123
        • Aún no reclutando
        • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
        • Contacto:
          • Marco Cattalini
      • Florence, Italia
        • Activo, no reclutando
        • Azienda Ospedaliera Universitaria Meyer IRCCS
      • Genova, Italia, 16147
        • Reclutamiento
        • IRCCS Istituto Giannina Gaslini
        • Contacto:
          • Roberta Caorsi
      • Milan, Italia, 20121
        • Aún no reclutando
        • ASST Fatebenefratelli Sacco
        • Contacto:
          • Angela Mauro
      • Milan, Italia, 20122
        • Activo, no reclutando
        • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
      • Roma, Italia, 00165
        • Aún no reclutando
        • Bambino Gesu Childrens Hospital
        • Contacto:
          • Camilla Celani
      • Siena, Italia, 53100
        • Aún no reclutando
        • Azienda Ospedaliera Universitaria Senese
        • Contacto:
          • Luca Cantarini
    • Trieste
      • Trieste, Trieste, Italia, 34137
        • Activo, no reclutando
        • Institute of Child and Maternal Health - IRCCS "Burlo Garofolo"

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

8 meses a 18 años (Niño, Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male and female patients.
  2. Parent or legal guardian written informed consent and child assent, if appropriate, are required before any assessment is performed.
  3. Diagnosis of relapse of pericarditis in a patient with previous diagnosis of acute pericarditis (idiopathic or secondary to invasive cardiac procedures).
  4. Inadequate response or intolerance to non-steroidal anti-inflammatory drugs or colchicine

Exclusion Criteria:

  1. Pericarditis secondary to a known infection (viral, bacterial, mycobacterial).

  2. Pericarditis in a patient with a previous diagnosis of any neoplasm and without complete recovery from at least one year.

  3. Pericarditis in the context of a systemic disease.

    1. Patients fulfilling diagnostic criteria for an autoimmune systemic disease
    2. Patients with a previous diagnosis of a genetically confirmed autoinflammatory disease
  4. Any conditions or significant medical problems, which in the opinion of the investigator places the patient at unacceptable risk for immunomodulatory therapy.

  5. Main alteration in the blood count

  6. Presence of Human Immunodeficiency Virus (HIV) infection, Hepatitis B or Hepatitis C infections.

  7. Evidence of active or latent tuberculosis (TB) determined by positive QuantiFERON (QFT-TB G In-Tube) test or positive Purified Protein Derivative (PPD) test (≥5 mm induration) within 2 months prior to randomization.

  8. Administration of any investigational drug or implantation of investigational device, or participation in another trial, within 30 days before screening.

  9. Use of steroids at the dosage of 1 mg/kg/day of prednisone or equivalent for at least 5 days in the 30 days before randomization.

  10. Live vaccinations within 1 months prior to the start of the trial and during the trial.

  11. Pregnancy, confirmed by a positive hCG laboratory test.

  12. Female adolescents (≤18 years of age) of childbearing potential who do not agree to abstinence or, if sexually active, do not agree to the use of contraception.

    -

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Arm 1: Steroids

Treatment with prednisone will be initiated at a dosage of 1 mg/kg/day (maximum 50 mg/day) in twice daily administration for 14 days. In case of complete response to treatment, prednisone will be reduced from day 14, otherwise it will be continued at 1 mg/kg/day until day 28 (week 4). Patients with complete response at day 28 will continue the study entering part 2, in which therapy will be progressively tapered.

In part 2, prednisone will be tapered progressively by 0.1-0.15 mg/kg/day of prednisone (or 5 mg in patients on the maximum dose of 50 mg/day) from current treatment every week until the break. If there is no relapse, treatment will be discontinued over a 10-week period. Patients will then be evaluated every 4 weeks until the end of the study (week 24).

Steroids will be progressively tapered with a reduction of 0,1-0,15 mg/kg/day of prednisone (or 5 mg in patients in treatment with the maximum dosage of 50 mg/day) from the ongoing treatment every week up to discontinuation. If a relapse does not occur, the treatment will be withdrawn in a period of time of 10 weeks.

Otros nombres:
  • Esteroide
  • Corticosteroide
Experimental: Arm 2: Anakinra

Treatment with anakinra will be initiated at a dose of 2 mg/kg/day (maximum dose 100 mg/day) as a single daily dose and maintained until day 28 (week 4).

Patients who achieve a complete treatment response at week 4 (day 28) will continue the study into Part 2. Patients without a complete treatment response will drop out of the study.

In Part 2 patients will continue daily anakinra treatment through week 12. The treatment will then be progressively reduced through the reduction of one weekly administration of the drug. The reductions will be made every 2 weeks until the interruption. Therefore, if no relapse occurs, treatment will be discontinued at week 24.

: Patients will continue daily treatment with anakinra up to week 12. Treatment will be then progressively tapered through the reduction of an administration of the drug per week. Reductions will be performed every 2 weeks up to discontinuation. Therefore, if a relapse does not occur, the treatment will be withdrawn at week 24.

Otros nombres:
  • Kineret

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants with complete response to treatment
Periodo de tiempo: Day 7

Complete response to treatment at day 7

Day 7
Number of participants with disease Flare
Periodo de tiempo: 3 months

Absence of flare after 3 months of therapy

3 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Time to response
Periodo de tiempo: Up to 24 weeks

Time to respond to treatment

Up to 24 weeks
Number of participants with improved Quality of life
Periodo de tiempo: Up to 24 weeks

Evaluation of quality of life through specific questionnaire

Up to 24 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

6 de febrero de 2025

Finalización primaria (Estimado)

1 de octubre de 2027

Finalización del estudio (Estimado)

31 de mayo de 2028

Fechas de registro del estudio

Enviado por primera vez

23 de marzo de 2023

Primero enviado que cumplió con los criterios de control de calidad

6 de abril de 2023

Publicado por primera vez (Actual)

10 de abril de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir